InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Replimune Group, Inc.

REPL Clue Score21
United States Fiscal year ends March CIK 0001737953 Results filed 28 Oct 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

32
Insider
Date
Role
Action
Shares
Price
Amount
Kapil Dhingra
2 Nov 2026
Director
Sold after exercise
21,500
$19.00
$408.50K
Kapil Dhingra
9 Dec 2025
Director
Sold after exercise
3,169
$10.40
$32.96K
Pamela Esposito
12 Sep 2023
Chief Business Officer
Sold after exercise
300
$20.00
$6.00K
Pamela Esposito
11 Sep 2023
Chief Business Officer
Sold after exercise
5,358
$20.01
$107.21K
Pamela Esposito
22 Aug 2023
Chief Business Officer
Sold after exercise
18,600
$20.01
$372.19K
Pamela Esposito
11 Aug 2023
Chief Business Officer
Sold after exercise
1,400
$20.00
$28.00K
Pamela Esposito
10 Jul 2023
Chief Business Officer
Sold after exercise
2,077
$21.12
$43.87K
Pamela Esposito
10 Jul 2023
Chief Business Officer
Sold after exercise
17,923
$21.63
$387.67K
Pamela Esposito
9 Dec 2022
Chief Business Officer
Sold after exercise
15,000
$25.03
$375.45K
Omega Fund IV, L.P.
14 Mar 2022
10% owner
Sold after exercise indirect
16,500
$15.42
$254.43K
Pamela Esposito
5 Aug 2021
Chief Business Officer
Sold after exercise
25,800
$35.09
$905.32K
Pamela Esposito
4 Aug 2021
Chief Business Officer
Sold after exercise
4,200
$35.00
$147.00K
Pamela Esposito
21 Jul 2021
Chief Business Officer
Sold after exercise
12,538
$33.17
$415.89K
Pamela Esposito
20 Jul 2021
Chief Business Officer
Sold after exercise
4,862
$33.05
$160.69K
Pamela Esposito
15 Jul 2021
Chief Business Officer
Sold after exercise
4,600
$33.37
$153.50K
Pamela Esposito
19 Jan 2021
Chief Business Officer
Sold after exercise
5,127
$42.38
$217.28K
Pamela Esposito
19 Jan 2021
Chief Business Officer
Sold after exercise
600
$43.24
$25.94K
Pamela Esposito
15 Jan 2021
Chief Business Officer
Sold after exercise
29,273
$43.58
$1.28M
Jean M. Franchi
14 Jan 2021
Chief Financial Officer
Sold after exercise
600
$44.00
$26.40K
Jean M. Franchi
14 Jan 2021
Chief Financial Officer
Sold after exercise
14,300
$44.55
$637.07K
Pamela Esposito
14 Jan 2021
Chief Business Officer
Sold after exercise
20,000
$45.02
$900.40K
Jean M. Franchi
13 Jan 2021
Chief Financial Officer
Sold after exercise
100
$44.19
$4.42K
Jean M. Franchi
14 Dec 2020
Chief Financial Officer
Sold after exercise
389
$42.09
$16.37K
Jean M. Franchi
14 Dec 2020
Chief Financial Officer
Sold after exercise
6,755
$42.86
$289.52K
Jean M. Franchi
14 Dec 2020
Chief Financial Officer
Sold after exercise
17,856
$43.70
$780.31K
Joseph P Slattery
8 Dec 2020
Director
Sold after exercise
5,200
$46.00
$239.20K
Kapil Dhingra
7 Dec 2020
Director
Sold after exercise
1,802
$47.04
$84.77K
Kapil Dhingra
7 Dec 2020
Director
Sold after exercise
13,523
$46.22
$625.03K
Kapil Dhingra
7 Dec 2020
Director
Sold after exercise
24,675
$45.09
$1.11M
Pamela Esposito
14 Oct 2020
Chief Business Officer
Sold after exercise
9,000
$35.04
$315.36K
Pamela Esposito
14 Oct 2020
Chief Business Officer
Sold after exercise
7,000
$30.15
$211.05K
Pamela Esposito
31 Aug 2020
Chief Business Officer
Sold after exercise
5,000
$27.05
$135.25K
Showing 250 of 279 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 282
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 25
Sales on a Rule 10b5-1 plan 9
Sales straight out of an exercise 32
Sales at will 226
Transactions with no price 0
Shares from compensation/vesting 31,126,773
Sales filed before the plan box existed 186
History held since 25 Jul 2018